RefleXion, Telix partner on high-risk cancer treatments

2020 03 12 17 01 2761 Reflexion Astro 2019 400

Radiation therapy equipment developer RefleXion Medical and radiopharmaceutical company Telix Pharmaceuticals are investigating the clinical utility of combining their technologies for improving treatments for high-risk prostate and aggressive kidney cancers.

Under their strategic collaboration agreement, the firms will assess the potential of several new Telix PET tracers, including gallium-68 prostate-specific membrane antigen-11 for prostate cancer and Zr-89-girentuximab for kidney cancer, for guiding RefleXion's biology-guided radiotherapy technology.

Page 1 of 592
Next Page